Electra Therapeutics’ IPO cash will support a potential first-in-class drug whose lead indication is a rare hyperinflammatory disorder with no FDA-approved treatments. Meanwhile, clinical-stage biotechs Marea Therapeutics and Sensorion revealed their respective plans to enter the U.S. public markets.

Sensorion, a French biotech with its U.S. outpost in Cambridge, is now weighing an initial public offering in the U.S.

Sensorion, already publicly traded in France, submitted a confidential draft registration statement with the US Securities and Exchange Commission.

France's ANSM has authorized the Phase I/II HearConnex clinical trial of Sensorion's SENS-601, with patient dosing targeted for early 2027.

Sensorion secures approval for HearConnex Phase I/II study in France  Clinical Trials Arena

Sensorion Wins Fast-Track French Approval for First SENS-601 Gene Therapy Trial  TipRanks

Looking back to May, the pharma and biotech sector saw a steady stream of senior leadership changes.

A strategic review determined that the development environment had "notably changed," leading Sensorion to end work on its gene therapy for OTOF-related hearing loss.

La biotech française Sensorion a annoncé mettre un terme à son programme de thérapie génique visant la surdité DFNB9. Elle se concentre désormais sur la surdité causée par une mutation sur le gène GJB...

Fin septembre, Sensorion a annoncé que l’essai clinique Audiogene visant à tester l’efficacité de la thérapie génique SENS-501 pour soigner les enfants atteints d’une surdité DFNB9 avait débuté.

The company highlights progress in its SENS-501 and GJB2-GT clinical programs, recent financing, and a leadership transition.

Sensorion has reported a six-month update from the Audiogene Phase I/II clinical trial’s cohort 2 assessing SENS-501, its gene therapy candidate for otoferlin-mediated congenital deafness.

Sensorion reports sustained efficacy in gene therapy hearing trial

Sensorion on Mar 23, 2026 reported a 12-month mean PTA gain of 14.5 dB in n=18 patients with no treatment-related SAEs, per company release and Investing.com.

Sensorion (ARNA) reported full-year 2025 results, provided a corporate update and released its annual report. Key clinical advances include SENS-501 six-month data expected Q1 2026 and SENS-601 (GJB2-GT) CTA submission targeted in H1 2026. The company completed a €60m private placement in Jan 2026, extending cash runway to end of H1 2027.Financials: 2025 net loss of €29.4m, R&D expenses of €28.8m, and cash & equivalents of €47.5m as of Dec 31, 2025.

Nawal Ouzren Chief Executive Officer to step down for personal reasons Amit Munshi, Chairman of Sensorion to assume role of Interim CEO MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced that Nawal Ouzren, …

Et si certaines formes de surdité pouvaient un jour être corrigées à la source ? C’est le pari de Sensorion.

The operation raised €60 million, a third of which came from Sanofi, which will hold 13.9% of the company's shares.